Drug Profile
Research programme: acellular pertussis combination vaccines - Biological E. Limited/Takeda
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Biological E Limited
- Developer Biological E Limited; Takeda
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pertussis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Pertussis(Prevention) in India (Parenteral, Injection)
- 26 Jun 2017 Biological E Limited in-licenses acellular pertussis vaccine technology from Takeda
- 26 Jun 2017 Early research in Pertussis (Prevention) in India (Parenteral)